Biotechnology journal · 2026
High-Yield Production and Cost-Effective Purification of an Alkali-Resistant Hexameric Protein A Variant for Antibody Affinity Chromatography.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Natal Carolina Mota, Lacombe Claudia, Zollner Alexander, Domingos Catarina, Mendes José, Nascimento André, Dias Ana Margarida Gonçalves Carvalho, Barbosa Arménio Jorge Moura, Peixoto Cristina, Wiltschi Birgit, Jungbauer Alois, Roque Ana Cecília Afonso
Аннотация
Recombinant Staphylococcal Protein A is the most widely used affinity ligand for industrial antibody purification, as well as for research and discovery of new antibodies. It has become a platform technology throughout the antibody manufacturing industry for the direct capture of products from a clarified cell culture supernatant. However, protein A adsorbents contribute significantly to manufacturing costs in the early stage of process development. In this work, we aimed to increase the production yield of an engineered protein A ligand comprising six repeats of the alkali-resistant protein A-derived Z domain, with a terminal cysteine residue for adsorbent immobilization (Z6AlkC). We coupled the extracellular production of Z6AlkC via secretion in high-cell-density, carbon-limited bioreactor cultures, with a simple and fast ultradiafiltration step for purification. Our bioprocess achieved 4 g/L of secreted Z6AlkC with an 89% purity, which is an improvement from previous reports that obtained intracellular expression and lower yield. We further purified the Z6AlkC protein by IgG-based affinity chromatography (Z6AlkC-P) and ultradiafiltration (Z6AlkC-F) and used it as an affinity ligand for antibody purification, as a proof of functionality. Both ligands yielded similar purification antibody behavior, showing that high-performance protein A-based ligands can be produced in scalable, high-productivity, and cost-effective methods.